233 related articles for article (PubMed ID: 21199580)
1. Cathepsin B: a potential prognostic marker for inflammatory breast cancer.
Nouh MA; Mohamed MM; El-Shinawi M; Shaalan MA; Cavallo-Medved D; Khaled HM; Sloane BF
J Transl Med; 2011 Jan; 9():1. PubMed ID: 21199580
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of cathepsin B activity attenuates extracellular matrix degradation and inflammatory breast cancer invasion.
Victor BC; Anbalagan A; Mohamed MM; Sloane BF; Cavallo-Medved D
Breast Cancer Res; 2011; 13(6):R115. PubMed ID: 22093547
[TBL] [Abstract][Full Text] [Related]
3. IL-8 and MCP-1/CCL2 regulate proteolytic activity in triple negative inflammatory breast cancer a mechanism that might be modulated by Src and Erk1/2.
Mohamed HT; El-Ghonaimy EA; El-Shinawi M; Hosney M; Götte M; Woodward WA; El-Mamlouk T; Mohamed MM
Toxicol Appl Pharmacol; 2020 Aug; 401():115092. PubMed ID: 32512068
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory and Non-inflammatory Breast Cancer: A Potential Role for Detection of Multiple Viral DNAs in Disease Progression.
El-Shinawi M; Mohamed HT; Abdel-Fattah HH; Ibrahim SA; El-Halawany MS; Nouh MA; Schneider RJ; Mohamed MM
Ann Surg Oncol; 2016 Feb; 23(2):494-502. PubMed ID: 26508152
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of cysteine proteases cathepsin B and cathepsin L in pancreatic adenocarcinoma.
Niedergethmann M; Wostbrock B; Sturm JW; Willeke F; Post S; Hildenbrand R
Pancreas; 2004 Oct; 29(3):204-11. PubMed ID: 15367886
[TBL] [Abstract][Full Text] [Related]
6. Immune phenotype of patients with stage IV metastatic inflammatory breast cancer.
Fernandez SV; MacFarlane AW; Jillab M; Arisi MF; Yearley J; Annamalai L; Gong Y; Cai KQ; Alpaugh RK; Cristofanilli M; Campbell KS
Breast Cancer Res; 2020 Dec; 22(1):134. PubMed ID: 33267869
[TBL] [Abstract][Full Text] [Related]
7. IL-10 correlates with the expression of carboxypeptidase B2 and lymphovascular invasion in inflammatory breast cancer: The potential role of tumor infiltrated macrophages.
Mohamed HT; El-Husseiny N; El-Ghonaimy EA; Ibrahim SA; Bazzi ZA; Cavallo-Medved D; Boffa MB; El-Shinawi M; Mohamed MM
Curr Probl Cancer; 2018; 42(2):215-230. PubMed ID: 29459177
[TBL] [Abstract][Full Text] [Related]
8. Cathepsin B Expression and the Correlation with Clinical Aspects of Oral Squamous Cell Carcinoma.
Yang WE; Ho CC; Yang SF; Lin SH; Yeh KT; Lin CW; Chen MK
PLoS One; 2016; 11(3):e0152165. PubMed ID: 27031837
[TBL] [Abstract][Full Text] [Related]
9. Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy.
Jhaveri K; Teplinsky E; Silvera D; Valeta-Magara A; Arju R; Giashuddin S; Sarfraz Y; Alexander M; Darvishian F; Levine PH; Hashmi S; Zolfaghari L; Hoffman HJ; Singh B; Goldberg JD; Hochman T; Formenti S; Esteva FJ; Moran MS; Schneider RJ
Clin Breast Cancer; 2016 Apr; 16(2):113-22.e1. PubMed ID: 26774497
[TBL] [Abstract][Full Text] [Related]
10. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC.
Iwase T; Harano K; Masuda H; Kida K; Hess KR; Wang Y; Dirix L; Van Laere SJ; Lucci A; Krishnamurthy S; Woodward WA; Layman RM; Bertucci F; Ueno NT
BMC Cancer; 2020 May; 20(1):430. PubMed ID: 32423453
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and outcome of bone-only metastasis in inflammatory and noninflammatory breast cancers.
Kai M; Kogawa T; Liu DD; Fouad TM; Kai K; Niikura N; Hsu L; Willey JS; Theriault RL; Valero V; Ueno NT
Clin Breast Cancer; 2015 Feb; 15(1):37-42. PubMed ID: 25258308
[TBL] [Abstract][Full Text] [Related]
12. Caveolin-1 mediates inflammatory breast cancer cell invasion via the Akt1 pathway and RhoC GTPase.
Joglekar M; Elbezanti WO; Weitzman MD; Lehman HL; van Golen KL
J Cell Biochem; 2015 Jun; 116(6):923-33. PubMed ID: 25559359
[TBL] [Abstract][Full Text] [Related]
13. Cell type-dependent pathogenic functions of overexpressed human cathepsin B in murine breast cancer progression.
Bengsch F; Buck A; Günther SC; Seiz JR; Tacke M; Pfeifer D; von Elverfeldt D; Sevenich L; Hillebrand LE; Kern U; Sameni M; Peters C; Sloane BF; Reinheckel T
Oncogene; 2014 Sep; 33(36):4474-84. PubMed ID: 24077280
[TBL] [Abstract][Full Text] [Related]
14. Cathepsin B expression in colorectal cancer in a Middle East population: Potential value as a tumor biomarker for late disease stages.
Abdulla MH; Valli-Mohammed MA; Al-Khayal K; Al Shkieh A; Zubaidi A; Ahmad R; Al-Saleh K; Al-Obeed O; McKerrow J
Oncol Rep; 2017 Jun; 37(6):3175-3180. PubMed ID: 28440429
[TBL] [Abstract][Full Text] [Related]
15. MARCKS protein overexpression in inflammatory breast cancer.
Manai M; Thomassin-Piana J; Gamoudi A; Finetti P; Lopez M; Eghozzi R; Ayadi S; Lamine OB; Manai M; Rahal K; Charafe-Jauffret E; Jacquemier J; Viens P; Birnbaum D; Boussen H; Chaffanet M; Bertucci F
Oncotarget; 2017 Jan; 8(4):6246-6257. PubMed ID: 28009981
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of caveolin-1 in inflammatory breast cancer cells enables IBC-specific gene delivery and prodrug conversion using histone-targeted polyplexes.
Ross NL; Sullivan MO
Biotechnol Bioeng; 2016 Dec; 113(12):2686-2697. PubMed ID: 27241022
[TBL] [Abstract][Full Text] [Related]
17. Hormonal-receptor positive breast cancer: IL-6 augments invasion and lymph node metastasis via stimulating cathepsin B expression.
Ibrahim SA; El-Ghonaimy EA; Hassan H; Mahana N; Mahmoud MA; El-Mamlouk T; El-Shinawi M; Mohamed MM
J Adv Res; 2016 Sep; 7(5):661-70. PubMed ID: 27482469
[TBL] [Abstract][Full Text] [Related]
18. MRI findings of inflammatory breast cancer, locally advanced breast cancer, and acute mastitis: T2-weighted images can increase the specificity of inflammatory breast cancer.
Uematsu T
Breast Cancer; 2012 Oct; 19(4):289-94. PubMed ID: 22351245
[TBL] [Abstract][Full Text] [Related]
19. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways.
Ibrahim SA; Gadalla R; El-Ghonaimy EA; Samir O; Mohamed HT; Hassan H; Greve B; El-Shinawi M; Mohamed MM; Götte M
Mol Cancer; 2017 Mar; 16(1):57. PubMed ID: 28270211
[TBL] [Abstract][Full Text] [Related]
20. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
